Clophelin (Clophelin)

Composition Pharmacodynamics Indications Carefully Contraindications Dosing and Administration Side effects Form release / dosage
Read on
Active substanceClonidineClonidine
Similar drugsTo uncover
  • Clophelin
    drops d / eye 
    MOSCOW ENDOCRINE FACTORY, FSUE     Russia
  • Clofelin injection for 0.01%
    solution in / in 
    ORGANICS, JSC     Russia
  • Cloppelin Tablets
    pills inwards 
    MOSCOW ENDOCRINE FACTORY, FSUE     Russia
    • Dosage form: & nbspeye drops
    Composition:

    1 ml of 0.125% solution contains:

    The current substance:

    Clonidine hydrochloride (clonidine) -1, 25 mg.

    Excipients:

    Sodium dihydrogen phosphate dihydrate is 9.88 mg.

    Sodium gidrofosphate dodecahydrate - 1.2 mg.

    Sodium chloride - 4, 0 mg.

    Water for injections - dabout 1 ml

    1 ml of 0.25% solution contains:

    Active substance:

    Clonidine hydrochloride (clonidine) - 2, 5 mg.

    Auxiliary thingsethe following:

    Sodium dihydrogen phosphate dihydrate is 9.88 mg.

    Sodium hydrophosphate dodecahydrate - 1, 2 mg.

    Sodium chloride 4.0 mg.

    Water for injections - dabout 1 ml.

    1 ml of 0.25% solution contains:

    The current substance:

    Clonidine hydrochloride (clonidine) - 5,0 mg.

    Auxiliary thingsethe following:

    Sodium dihydrogen phosphate dihydrate- 9.88 mg.

    Sodium hydrophosphate dodecahydrate -1, 2 mg.

    Sodium chloride 4.0 mg.

    Water for injections - dabout 1 ml.

    Description:

    Transparent colorless liquid.

    Pharmacotherapeutic group:Hypotensive central agent
    ATX: & nbsp
  • Clonidine
    • Pharmacodynamics:

    When instilling clonidine solution into conjunctivalth the sacrangement of intraocular pressure is due to local adrenomimetic action, as well as the weakening of the sympathetic tone due to the central effect of the resorptive part of the drug. Decrease in intraocular pressure is caused by reduction of production of intraocular fluid and to some extent by improvement of its outflow.

    Pharmacokinetics:

    Local drug, pharmacodynamics has not been studied.

    Indications:

    Primary opengotal glaucoma (as a monotherapy or in combination with other medications that reduce intraocular pressure).

    Contraindications:

    Hypersensitivity, expressed atherosclerosis of cerebral vessels, arterial hypotension, depressive states, pregnancy, lactation, children's age to 18 years.

    Carefully:

    Recently suffered myocardial infarction, chronic renal failure.

    Pregnancy and lactation:

    RThe results of clinical studies of clonidine in beremaMr.are limited. Application during pregnancy is contraindicated. Clonidine penetrates into breast milkabout. so when Mr.The need for preparation During lactation,toratify goreMr.th feeding.

    Dosing and Administration:Bury in the conjunctival bag for 1-2 drops 2-4 times a day. Treatment begins with the appointment of 0.25% solution. In case of insufficient decrease in intraocular pressure, a 0.5% solution is used. With the development of side effects associated with the use of 0.25% solution, 0,125% solution.
    Side effects:

    Local reactions: dry conjunctiva, itching or burning in the eyes.

    Systemic reactions: dry mouth, drowsiness, weakness, constipation, lowering of blood pressure, bradycardia. Usually these effects gradually weaken and in a few days they can pass.

    Overdose:

    Increases the severity of side effects. The drug is canceled. Treatment is symptomatic.

    Interaction:

    Do not prescribe antidepressants and large doses of antipsychotic drugs (neuroleptics).

    Special instructions:

    If there is no effect in the flowetioneThe drug is canceled for 1-2 days. With prolonged use of clonidine solution, it is necessary to regularly monitor the intraocular pressure. At its or his increase it is necessary to change a medicinal hypotensive mode.

    To reduce the systemic effect of the drug after instillation, it is necessary to 1-2 minutes to press the finger of the lacrimal sac.

    Effect on the ability to drive transp. cf. and fur:

    During treatment due to sedation, care must be taken when driving vehicles and engaging in other potentially dangerous activities that require an increased concentration of attention and speed of psychomotor reactions.

    Form release / dosage:

    Eye drops 0.125%, 0.25% and 0.5%.

    Packaging:

    1.3 ml, 1.5 ml, 2 ml or 5 ml in a tube-dropper polymer.

    1, 2, 4, 5 or 10 tubes with instructions for the use of the drug in a pack of cardboard.

    A text and a graphic image (pictograms) of instructions for the use of a tube-dropper are applied to the pack.

    5 ml or 10 ml into the bottle-dropper polymer.

    1 or 2 vials of a dropper with instructions for the use of the drug in a pack of cardboard. A text and graphic image (pictograms) of instructions for the use of a dropper are applied to the pack.

    Storage conditions:

    In accordance with the rules for storage of potent substances. In the dark place at a temperature of no higher than 15 ° C. Keep out of the reach of children.

    Shelf life:2 years. Do not use after the expiration date printed on the package.
    Terms of leave from pharmacies:On prescription
    Registration number:P N001080 / 01
    Date of registration:17.10.2008 / 17.04.2017
    Expiration Date:Unlimited
    The owner of the registration certificate:MOSCOW ENDOCRINE FACTORY, FSUE MOSCOW ENDOCRINE FACTORY, FSUE Russia
    Manufacturer: & nbsp
    Representation: & nbspMOSCOW ENDOCRINE FACTORY FGUP MOSCOW ENDOCRINE FACTORY FGUP Russia
    Information update date: & nbsp30.01.2018
    Illustrated instructions
      Instructions
      Up